COVID-19 (Coronavirus) Update: Testing and Information | Vaccine Updates | Visitor Guidelines

Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineer NY-ESO-1 Specified (c259) T Cells, Alone or in combination with other agents, in HLA-A@+ Participants with NY-ESO-1 and/or LAGE -1a Positive Solid Tumors

Protocol No
GSK-3377794-208467-SARCOMA
Principal Investigator
John Charlson
Phase
II
Summary
People with synovial sarcoma will be given a study drug GSK3377794. The purpose of this study is to help answer the following questions: -Can GSK3377794 help participants with synovial sarcoma? -How safe is GSK3377794 and what side effects may be related to taking it? -Does your tumor affect how GSK3377794 works?
Description
Study of Genetically Engineered T Cells in NY-ESO-1 +/or LAGE-1a + Solid Tumors
Participating Institutions
Froedtert Hospital
Status
OPEN TO ACCRUAL
Sub Category